18,890 Shares in DexCom, Inc. $DXCM Acquired by BDF Gestion

BDF Gestion acquired a new stake in DexCom, Inc. (NASDAQ:DXCM) in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund acquired 18,890 shares of the medical device company’s stock, valued at approximately $1,630,000.

A number of other institutional investors have also recently made changes to their positions in DXCM. Legal & General Group Plc purchased a new position in shares of DexCom in the second quarter worth $173,237,000. Deutsche Bank AG purchased a new stake in DexCom during the 2nd quarter valued at $164,035,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in DexCom by 15.6% during the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 11,261,876 shares of the medical device company’s stock valued at $758,487,000 after buying an additional 1,515,702 shares during the period. SG Americas Securities LLC boosted its position in DexCom by 271.4% during the 1st quarter. SG Americas Securities LLC now owns 2,065,277 shares of the medical device company’s stock valued at $129,699,000 after buying an additional 1,509,219 shares during the period. Finally, Mitsubishi UFJ Asset Management Co. Ltd. bought a new stake in DexCom in the 2nd quarter worth $89,940,000. Hedge funds and other institutional investors own 97.75% of the company’s stock.

Insider Buying and Selling

In other news, EVP Sadie Stern sold 2,565 shares of the company’s stock in a transaction that occurred on Monday, September 28th. The shares were sold at an average price of $86.15, for a total value of $220,974.75. Following the transaction, the executive vice president owned 123,478 shares in the company, valued at approximately $10,637,629.70. This represents a 2.04% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Mark Foletta sold 2,000 shares of the company’s stock in a transaction that occurred on Monday, August 3rd. The shares were sold at an average price of $85.32, for a total value of $170,640.00. Following the completion of the transaction, the director directly owned 48,852 shares in the company, valued at $4,168,052.64. This trade represents a 3.93% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 22,557 shares of company stock worth $1,903,857 over the last quarter. 0.28% of the stock is owned by insiders.

DexCom Trading Down 0.3%

DXCM stock traded down $0.22 on Monday, reaching $85.82. The company’s stock had a trading volume of 775,143 shares, compared to its average volume of 4,962,913. The firm has a market cap of $32.39 billion, a PE ratio of 33.97, a PEG ratio of 1.44 and a beta of 1.48. The business has a fifty day simple moving average of $87.61 and a two-hundred day simple moving average of $75.96. DexCom, Inc. has a 12-month low of $54.11 and a 12-month high of $92.59. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.43 and a current ratio of 1.73.

DexCom (NASDAQ:DXCM) last released its quarterly earnings results on Thursday, July 30th. The medical device company reported $0.70 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.61 by $0.09. The company had revenue of $1.31 billion during the quarter, compared to the consensus estimate of $1.29 billion. DexCom had a net margin of 20.12% and a return on equity of 35.94%. DexCom’s revenue was up 13.1% on a year-over-year basis. During the same period in the prior year, the firm earned $0.48 earnings per share. As a group, research analysts forecast that DexCom, Inc. will post 2.64 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on the stock. Citigroup restated a “buy” rating and issued a $88.00 price objective (up from $84.00) on shares of DexCom in a research report on Friday, July 31st. Benchmark upped their price objective on shares of DexCom from $77.00 to $82.00 and gave the company a “buy” rating in a research note on Friday, July 31st. Truist Financial set a $102.00 target price on shares of DexCom and gave the stock a “buy” rating in a report on Friday, September 18th. TD Cowen reissued a “buy” rating and issued a $95.00 target price on shares of DexCom in a research note on Friday, September 18th. Finally, Argus raised their target price on DexCom from $86.00 to $96.00 and gave the stock a “buy” rating in a research note on Tuesday, August 4th. Three investment analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and two have given a Hold rating to the company. According to MarketBeat, DexCom has a consensus rating of “Buy” and a consensus target price of $92.43.

DexCom Profile

DexCom, Inc develops and commercializes continuous glucose monitoring (CGM) systems for people with diabetes. Its devices use a small wearable sensor to measure glucose levels in real time and transmit readings to compatible smartphones, receivers, smartwatches, and other connected devices, helping users monitor glucose trends and make informed decisions about their health.

The company’s product portfolio includes the Dexcom G7 and Dexcom G6 CGM systems, as well as Dexcom ONE and Dexcom ONE+ products offered in select markets.